Metabolic syndrome - Cardiovascular disease risk and more

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 22, Issue 2, 2005, Pages 1-2

  Carulli, N ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

BLOOD PRESSURE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; GLUCOSE BLOOD LEVEL; HEALTH CARE ORGANIZATION; HEPATITIS C VIRUS; HEREDITY; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIVER GRAFT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; STEATOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD; WAIST CIRCUMFERENCE;

EID: 27644501402     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02586.x     Document Type: Editorial

References (12)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004; 33: 283-303.
3. Marchesini G, Brizi M, Blanchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
4. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18: 353-8.
5. Carulli N, Loria P. Chronic hepatopathies: from cryptogenetics to multiple factors. Ann Ital Med Int 2003; 18: 57-9.
6. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
7. Gupte P, Amarapurkar D, Agal S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004; 19: 854-8.
8. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
9. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-92.
10. Negro F. Hepatitis C virus and liver steatosis: when fat is not beautiful. J Hepatol 2004; 40: 533-5.
11. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
12. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.